GBI Research has built up a portfolio of compelling business intelligence reports showcasing progressive and data-driven analysis across the oncology therapy area. Our reports combine innovative analytical methodologies leveraging industry-leading databases, with authoritative commentary and novel insights.
Oncology has more pipeline activity than any other therapy area across the industry
GBI Research has an extensive range of reports exploring this activity and innovation across different indications and disease areas.
Reports Include:
Ocular Cancer Drug Development Pipeline Review, 2018
Single user price: $3,995
Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018
Single user price: $3,995
Breast Cancer Therapeutics in Asia-Pacific Markets to 2024 – Growth Driven by Increasing Uptake of Targeted Therapies and Rising Prevalence
Single user price: $4,995
Global Cancer Immunotherapies Market to 2024 – Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline
Single user price: $4,995
Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 – Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market
Single user price: $4,995
Frontier Pharma: Breast Cancer – First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline Diversification for Late-Stage Breast Cancer
Single user price: $6,995
Report Information:
Published: 2018
Publisher: GBI Research
Report Format: electronic pdf
